Exploring the Mechanism of Astragalus membranaceus in the Treatment of Post-Infectious Irritable Bowel Syndrome Based on Random Walk with Restart Algorithm and Experimental Validation
DOI:
https://doi.org/10.62767/jecacm502.0420Keywords:
Astragalus membranaceus, randomized walk with restart algorithm, post-infectious irritable bowel syndrome, TLR4Abstract
Background: This study aims to screen target genes with high relevance by running the random walk with restart (RWR) algorithm on the target background network, and to explore the mechanism of Astragalus membranaceus (AM) mediating targets in the treatment of post-infectious irritable bowel syndrome (PI-IBS) by experimental validation. Methods: AM active ingredients were retrieved from TCMSP and HERB databases, of which target genes were predicted by SwissTargetPrediction. The disease genes were obtained by retrieving irritable bowel syndrome (IBS) from disease databases, and integrated to AM target genes to obtain "AM-IBS" intersection genes. The RWR algorithm was used to identify "AM-IBS" crossover genes, and target genes were screened based on correlation scores. The rat model of PI-IBS was established by multiple compound stimulation, followed by treatment with different doses of AM (0.2, 1, 2 g/(kg·d)). Intestinal function of rats was assessed by measuring fecal water content and body weight. Sucrose preference test and open-field test were performed to assess changes in behaviors of rats during the experiment. The expression of Toll-like receptor 4 (TLR4) in colon tissues was detected by immunohistochemistry, and the co-localized expression pattern of polymerase I and transcript release factor (PTRF) /TLR4 was observed by immunofluorescence. Results: At the end of the modeling, the body weight of PI-IBS rats was decreased, but fecal water content, levels of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), as well as depressionand anxiety-like behaviors were increased, all of which were improved to varying degrees after AM treatment. Moreover complex stimulation of rats with EPSD, TNBS and CUMS induced higher levels of anxiety and depression, while AM treatment reduced anxiety and depression levels. Notably, AM treatment could inhibit the overexpression of TLR4. Conclusion: Astragalus membranaceus has a certain therapeutic effect on PI-IBS and may improve PI-IBS symptoms by regulating the PTRF/TLR4-related pathway.
References
Mumolo MG, Bertani L, Ceccarelli L, et al. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World Journal of Gastroenterology 2018; 24(33): 3681-3694.
Gu QY, Zhang J. The research advances in the pathogenesis of irritable bowel syndrome. Chinese Journal of Gastroenterology and Hepatology 2017, 26(12): 1420-1423.
Su DM, Zhang SS, Liu JP, et al. Systematic review of D-IBS treated by Chinese herbal medicine. China Journal of Traditional Chinese Medicine and Pharmacy 2009; 24(04): 532-535.
Yang L, Li AP, Zhang WN, et al. Research progress on pharmacological effects and clinical application of single Astragali Radix and classical formulae containing Astragali Radix in treatment of kidney disease. Chinese Traditional and Herbal Drugs 2018; 49(14): 3419-3424.
Zhang Q, Gao WY, Man SL. Chemical composition and pharmacological activities of Astragali Radix. China Journal of Chinese Materia Medica 2012; 37(21): 3203-3207.
Chen GH, Huang WF. Progress in pharmacological effects of compositions of Astragalus membranaceus. Chinese Journal of New Drugs 2008; 17(17): 1482-1485.
Graziani V, Esposito A, Scognamiglio M, et al. Spectroscopic characterization and cytotoxicity assessment towards human colon cancer cell lines of acylated cycloartane glycosides from Astragalus boeticus L. Molecules 2019; 24(9): 1725.
Shkondrov A, Krasteva I, Bucar F, et al. A new tetracyclic saponin from Astragalus glycyphyllos L. and its neuroprotective and hMAO-B inhibiting activity. Natural Product Research 2020; 34(4): 511-517.
Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. The American Journal of Gastroenterology 2009; 104 Suppl 1: S1-S35.
Bensoussan A, Talley NJ, Hing M, et al. Treatment of irritable bowel syndrome with Chinese herbal medicine: A randomized controlled trial. JAMA 1998; 280(18): 1585-1589.
Saha L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World Journal of Gastroenterology 2014; 20(22): 6759-6773.
Zhou HH, Zhang YM, Zhang SP, et al. Suppression of PTRF alleviates post-infectious irritable bowel syndrome via downregulation of the TLR4 pathway in rats. Frontiers in Pharmacology 2021; 12: 724410.
Yang J, Tian S, Zhao J, et al. Exploring the mechanism of TCM formulae in the treatment of different types of coronary heart disease by network pharmacology and machining learning. Pharmacological Research 2020; 159: 105034.
Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Journal of Cheminformatics 2014; 6: 13.
Yuan F, Pan X, Chen L, et al. Analysis of protein-protein functional associations by using gene ontology and KEGG pathway. BioMed Research International 2019; 2019: 4963289.
Wang FY, Su M, Zheng YQ, et al. Herbal prescription Chang'an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome. Acta Pharmacologica Sinica 2015; 36(6): 708-715.
Ma X, Wang X, Kang N, et al. The effect of Tong-Xie-Yao-Fang on intestinal mucosal mast cells in postinfectious irritable bowel syndrome rats. Evidence-Based Complementary and Alternative Medicine 2017; 2017: 9086034.
Qin HY, Xiao HT, Wu JC, et al. Key factors in developing the trinitrobenzene sulfonic acidinduced post-inflammatory irritable bowel syndrome model in rats. World Journal of Gastroenterology 2012; 18(20): 2481-2492.
Chen Y, Zhao Y, Luo DN, et al. Electroacupuncture regulates disorders of gut-brain interaction by decreasing corticotropin-releasing factor in a rat model of IBS. Journal of Gastroenterology Research and Practice 2019; 2019: 1759842.
Geng X, Wu H, Li Z, et al. Jie-Yu-He-Huan Capsule Ameliorates Anxiety-Like Behaviours in Rats Exposed to Chronic Restraint Stress via the cAMP/PKA/CREB/BDNF Signalling Pathway. Oxidative Medicine and Cellular Longevity 2021; 2021: 1703981.
Ribeiro-Carvalho A, Lima CS, Nunes-Freitas AL, et al. Exposure to nicotine and ethanol in adolescent mice: effects on depressive-like behavior during exposure and withdrawal. Behavioural Brain Research 2011; 221(1): 282-289.
Farooq M, Batool M, Kim MS, et al. Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies. Frontiers in Cell and Developmental Biology 2021; 9: 756315.
Yu L, Zhang Y, Chen Q, et al. Formononetin protects against inflammation associated with cerebral ischemia-reperfusion injury in rats by targeting the JAK2/STAT3 signaling pathway. Biomedicine & pharmacotherapy 2022; 149: 112836.
Wang JY, Jiang MW, Li MY, et al. Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation. The Journal of Nutritional Biochemistry 2022; 100: 108899.
Jia C, Hu F, Lu D, et al. Formononetin inhibits IL-1β-induced inflammation in human chondrocytes and slows the progression of osteoarthritis in rat model via the regulation of PTEN/AKT/NF-κB pathway. International Immunopharmacology 2022; 113(Pt A): 109309.
Chen B, Zhu S, Du L, et al. Reduced interstitial cells of Cajal and increased intraepithelial lymphocytes are associated with development of small intestinal bacterial overgrowth in post-infectious IBS mouse model. Scandinavian Journal of Gastroenterology 2017; 52(10): 1065-1071.
Compare D, Rocco A, Coccoli P, et al. Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome. BMC Gastroenterology 2017; 17(1): 53.
Zheng Y, Lee S, Liang X, et al. Suppression of PTRF alleviates the polymicrobial sepsis induced by cecal ligation and puncture in mice. The Journal of Infectious Diseases 2013; 208(11): 1803-1812.
Wang H, Pilch PF, Liu L. Cavin-1/PTRF mediates insulin-dependent focal adhesion remodeling and ameliorates highfat diet-induced inflammatory responses in mice. The Journal of Biological Chemistry 2019; 294(27): 10544-10552.
Tang S, Liu W, Zhao Q, et al. Combination of polysaccharides from Astragalus membranaceus and Codonopsis pilosula ameliorated mice colitis and underlying mechanisms. Journal of Ethnopharmacology 2021; 264: 113280.
Hou M, Leng Y, Shi Y, et al. Astragalus membranaceus as a Drug Candidate for Inflammatory Bowel Disease: The Preclinical Evidence. The American Journal of Chinese Medicine 2023; 51(6): 1501-1526.
He J, Li X, Yang S, et al. Protective effect of Astragalus membranaceus and its bioactive compounds against the intestinal inflammation in Drosophila. Frontiers in Pharmacology 2022; 13: 1019594.
Park YE, Moon HS, Yong D, et al. Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases. Scientific Reports 2022; 12(1): 6359.
Zhang S, Zhu P, Yuan J, et al. Non-alcoholic fatty liver disease combined with rheumatoid arthritis exacerbates liver fibrosis by stimulating co-localization of PTRF and TLR4 in rats. Frontiers in Pharmacology 2023; 14: 1149665.
Nagahara T, Ohno K, Nagao I, et al. Association between intestinal lymphangiectasia and expression of inducible nitric oxide synthase in dogs with lymphoplasmacytic enteritis. The Journal of Veterinary Medical Science 2022; 84(1): 20-24.
Published
Data Availability Statement
The data presented in this study are available on request from the corresponding author.
Issue
Section
License
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
